Documente Academic
Documente Profesional
Documente Cultură
INVAZIA LOCALA SI
METASTAZAREA
Cretere necontrolat
Reducerea Independena fa
sensibilitii la de semnalele
apoptoz inhibitorii
Cancer
Dezvoltarea i
meninerea unei Invazia i
vascularizaii tumorale
(angiogenez)
metastazarea
ESENIALE:
1. Invazia i motilitatea
Laminina
Collagenul
Vitronectina
Semnalizarea prin integrine i receptorii factorilor de cretere permite celulelor tumorale
s detecteze polaritatea i ataarea de MEC
Procesul de invazie local n trei etepe
Aderarea
After losing attachment with neighbors, malignant cells interact with the ECM in order to
degrade, remodel, attach, and invade through this matrix.
Integrine signaling works together with growth factor receptors by allowing cells to
sense ECM attachment and polarity.
Bariere externe- matricea extracelular ce limiteaz
progresia tumoral
Organism= compartiment celular + matricea
extracelulara
Matricea extracelular (MEC) = membrana bazala (MB) +
stroma interstiial i de organ
Cytoskeleton modification
Invazia tisular i METASTAZAREA
Aplicaii clinice:
semntura metastazrii (identificarea unui set de gene de metastazare)
rol prognostic + decizii terapeutice;
ex., MammaPrint test i Oncotype Dx pentru cancerul de sn
terapii intite;
18
Micromediul tumoral acioneaz ca un factor
de presiune selectiv asupra celulelor tumorale
Celule endoteliale
Celule imune
Pericite inflamatorii
Tumorile prezint o
varietate de celule ale
sistemului imun care
contribuie la formarea
stromei esutului malign.
Tumorile posed celule
infiltrante aparinnd att
sistemului imun nativ ct i
celui de adaptare precum
MDSC, macrofage, DC,
mastocite, eosinofile,
neutrofile, celule NK i
limfocite. Aceste celule
formeaz o reea reglatorie
complex care stimuleaz
proliferarea tumoral si
creeaz un mediu permisiv
pentru eludarea
INTERACIUNILE DINTRE CELULELE TUMORALE I
STROM
21
Cancer mamar
ANGIOGENEZA
Angiogeneza este esentiala pentru nutriia, creterea i
supravieuirea celulei tumorale
1. Folkman. In: Kufe, Pollock, Weichselbaum, eds. Cancer Medicine (Holland). 6th ed. Hamilton, Ontario: BC Decker; 2000
2. Bergers, Benjamin. Nat Rev Cancer 2003; 3. Folkman. NEJM 1971; 4. Folkman. J Natl Cancer Inst 1990
Angiogenesis: essential for Tumor Growth
and Malignant Progression
Under hypoxic conditions, the hypoxia inducible factor (HIF) transcriptional regulatory
proteins HIF-1 and HIF-2 are no longer hydroxylated by a family of oxygen-
regulated proline hydroxylases (PHD1-3), which disables the binding of the von
Hippel-Lindau (VHL) tumor suppressor protein.
By adapting to the selective pressure of hypoxia, tumor cells acquire the ability to
withstand harsher microenvironments by switching to glycolysis
resisting cell death
inducing angiogenesis
invading through the ECM
Both expression of HIF-1 levels and tumor hypoxia predict for worse overall survival
and a higher risk for metastasis
Mediatori moleculari ai angiogenezei tumorale
PROANGIOGENIC ANTIANGIOGENIC
______________________________________________________________
VEGF-A, VEGF-B, VEGF-C Trombospodin (TSP1)
PDGF Angiogstatin
FGF (FDF2, FGF1) Arrestin (fragment de colagen IV)
Angiopoietin (ANG1, ANG2) Canstatin (fragment de colagen IV)
IL 8 Tissue inhibitors of
TNF- metalloproteinases (TIMP)
IFN-, IFN-
Acid retinoic
Fibronectin
Endostatin
Angiogenesis un pas esential in progresia
tumorala
Angiogeneza + Limfangiogeneza = Love
Era terapiei antiangiogenice
6
VEGF: element central al angiogenezei tumorale
Hypoxia PDGF
IGF-1
EGF
IL-8
Binding and activation
VEGF release of VEGFR
bFGF
COX-2
Nitric oxide
Oncogenes
Increased expression
(MMP, tPA, uPA, uPAr,
eNOS, etc.)
VEGF
VEGFR-2
Ribozymes
Agenii anti-angiogenici
Distrugerea MB vasculare;
Cancer cells can mimic leukocytes and bind to endothelial E- and P-selectins.
Many cancers such as breast and prostate will not give rise to metastasis until
10 or even 20 years after eradication of the primary tumor.
Stephen Paget
1855 1926
Un model integrat al metastazarii
Somatic evolution of cancer during growth at the primary site results in the
selection of tumorigenic functions (light blue) that are fulfilled by
tumorigenic genes.
Metastasis-specific functions are considered those that act on tumor cells
after intravasation and enable them to home to, penetrate, or colonize
distant organs (orange). Genes that provide such functionality are
Interactions between cancer and
the bone microenvironment lead to
a vicious cycle. Cancer cells can
migrate to the bone
microenvironment under the
influence of CXCL12, which also
leads to cell activation and
migration via CXCR4.
The tumor cell secretes factors that
promote osteoclast differentiation
such as osteopontin (OPN) and
interleukin-11 (IL-11).
Proteases such as matrix
metalloproteinase 1 (MMP1) and
MMP7 are also secreted.
Parathyroid hormone-related
protein (PTHrP) can lead to
production of membrane bound
RANKL on osteoblasts. This leads to
RANK-mediated osteoclast
activation.
Other cytokines may also inhibit
production of osteoprotegerin
(OPG), which antagonizes
Rolul sistemului imun n metastazare
Sexual behavior is probably largely a surrogate for the risk of exposure to HPV.
*
Routine Screening and Early Detection for Cervical Cancer
and its Prevention
Colposcopy
Pap Smear
Rolul depistrii precoce este bine stabilit n cancerul de col uterin, mortalitatea prin
acest tip de cancer scznd cu circa 70% n ultimii 30 de ani n rile cu programe
de screening eficiente.
Screening-ul cancerului de col uterin const din examinarea de rutin a frotiului
citologic cervico-vaginal Babe-Papanicolau (Pap-test).
Persoanele cu anumii factori de risc (infecie cu HIV, imunosupresie, expunerea in
utero la dietilstilbestrol, tratament prealabil pentru o displazie neoplazie
intraepitelial cervical [CIN] de grad 2/3, sau pentru cancer cervical) trebuie
screenate la intervale mai reduse. Vrsta maxim pentru screening-ul cancerului de
col uterin nu este clar definit.
Aspectele citologice (normal, displazie/CIN, malign) sunt clasificate actual dup
sistemul Bethesda. Dac rezultatele unui test Papanicolau sunt pozitive, se va
recomanda colposcopia, eventual cu utilizare de acid acetic glacial. Leziunile
epiteliului cervical (displaziile) cu grad redus de risc vor fi urmrite periodic, pn la
remisiune/progresie, iar cele cu risc crescut trebuie tratate prin proceduri loco-
regionale ablative/excizionale.
Cea mai important problem n depistarea precoce a cancerelor de col uterin
rmne aceea legat de atragerea unui numr ct mai mare de femei n aciunea
de screening, mai cu seam din categoria celor cu factori de risc crescut
SCREENINGUL CANCERULUI MAMAR
Breast Cancer
* The indications for genetic testing in breast cancer and in other cancers are in rapid
evolution as the true risks become better defined and as prevention (e.g., tamoxifen)
and early detection (e.g., mammography, MRI) strategies mature.
Cancerul mamar
Mijloace de screening
Mammography
Breast self
examination
(BSE)
MRI
Clinical breast
examination
(CBE)
Ultrasound
Metode de screening
Mammography
Relative breast cancer-specific mortality decreased by 15%
Absolute mortality benefit for annual screening starting at age 40 = 4 per 10,000
at 10.7 years, vs. 5 per 1,000 for women screened annually starting at age 50
Absolute benefit approximately 1% overall, but depends on inherent breast
cancer risk, which rises with age
CBE
BC mortality similar for women aged 50-59 undergoing screening CBEs with or
without mammograms.
BSE
No difference in breast cancer mortality seen after 10 years; 40% of women
enrolled, however, were younger than 40 years.
http://www.cancer.gov/cancertopics/pdq/screening/breast/healthprofessional#Section_175
Cancer mamar- studii de screening
Screening of women at high risk for familial breast cancer by mammography,
ultrasonography, and MRI: sensitivity and specificity of each modality
Screening
Normal risk
Rectosigmoidoscopia flexibil
Nu necesit sedare
Mai ieftin
Colonoscopia normal
A- Asimetrie
B- Border - margini
C- Culoare
D- Diametru
E- Elevation - supradenivelare
Malignant Melanoma
Summary of All Cancer Screening
Test Sensitivity Specificity % Positive in practice
I. BREAST CANCER
Film screen mammography 77-96% 94% 10-12%
Digital mammography 64% 86% 12%
Clinical breast examination 17-58% 94% 7%
Breast self-examination 42-72% N/A N/A
Clinical evaluation